Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients

Author:

Radbruch Lukas,Sabatowski Rainer,Petzke Frank,Brunsch-Radbruch Anke,Grond Stefan,Lehmann Klaus A1

Affiliation:

1. Department of Anaesthesiology, University of Cologne

Abstract

Transdermal fentanyl was released in Germany in 1995. From October 1996 to February 1998 transdermal treatment was documented for 1005 patients (506 men and 499 women with a mean age of 60 years, range 20–92 years) with chronic pain in an open survey including 290 physicians from hospitals and general practitioners throughout Germany. Most patients suffered from cancer pain and only 11 patients had chronic pain from non-malignant disease. Physicians were asked to complete a questionnaire for patients treated with transdermal fentanyl on initiation of therapy (day 0), and days 3, 6, 18, 30 thereafter, followed by monthly follow-up intervals. Patients were asked to complete a pain diary. Transdermal therapy was documented from day 0 for 824 patients, while 181 patients had been treated with transdermal fentanyl before admission in the survey. Most of the other 824 patients had been treated with other step 3 opioids (55% of the patients) or step 2 opioids (23%) before conversion to transdermal fentanyl, whereas 8% had been treated only with non-opioids and 14% had received analgesics only as required or not at all before initiation of transdermal therapy. The most important reasons for switching to transdermal opioid therapy were insufficient pain relief with the previous medication followed by a variety of gastrointestinal symptoms impeding oral analgesic therapy. Initial fentanyl doses ranged from 0.6 to 9.6 mg/day (25 to 400 [.mu]g/h) with a median of 1.2 mg/day (50 [.mu]g/h). Median doses slowly increased throughout the observation period to 2.4 mg/day (100 [.mu]g/h) after 4 months of treatment. Most patients continued transdermal therapy until the time of death (47% of patients). Other reasons for discontinuation were inadequate pain relief (10%), pain relief with other analgesic regimens (10%), other symptoms than pain (5%), rejection of transdermal therapy by the patient (6%) or miscellaneous (16%). Adverse events were documented as the reason for discontinuation of transdermal therapy in 49 patients (5%). Dyspnoea was documented for seven patients as the reason for discontinuation. One of these patients, as well as another patient with an episode of apnoea, had to be treated with artificial respiration for several hours, but both patients recovered without sequelae. Transdermal therapy with fentanyl was safe and efficient in this national survey. Transdermal fentanyl can be recommended for treatment of moderate to severe cancer pain and probably may even be used as a first-line drug on step 3 of the World Health Organization recommendations in selected patient groups.

Publisher

SAGE Publications

Subject

Anesthesiology and Pain Medicine,General Medicine

Reference50 articles.

1. Arzneimittelkommission der Deutschen Ärzteschaft. Empfehlungen zur Therapie von Tumorschmerzen. Arzneiverordnung in der Praxis 1996; Suppl 2.

2. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study

3. WHO-Empfehlungen zur Tumorschmerztherapie

Cited by 82 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Transdermal Fentanyl in Patients with Cachexia—A Scoping Review;Cancers;2024-09-05

2. Schmerztherapie in der Palliativmedizin;AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie;2023-02

3. Schmerztherapie in der Palliativmedizin;Palliativmedizin;2023

4. Analgetika;Arzneimitteltherapie in der Palliativmedizin;2022

5. Current management of cancer pain in Italy: Expert opinion paper;Open Medicine;2021-12-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3